-
This Looks to Be Johnson & Johnson's Next Blockbuster Drug
Post on 10/6/16
-
Immunomedics Announces $30 Million Financing
Post on 10/5/16
-
What Clinton and Trump Would Do to Medicare
Post on 10/5/16
-
Tabula Rasa HealthCare Closes IPO
Post on 10/5/16
-
Daiichi Sankyo Announces New Strategic Immuno-Oncology Research Collaboration with AgonOx
Post on 10/4/16
-
NJ Spine and Wellness Celebrates with Grand Opening Event at New Freehold Location
Post on 10/4/16
-
Instant Analysis: Celgene Pays $600 Million for Swiss Biotech
Post on 10/4/16
-
Ember Therapeutics Signs Endorsement Deal with 12 Time Olympic Medalist Ryan Lochte
Post on 10/4/16
-
Healthcare2U Expands into the Northeast
Post on 10/3/16
-
Premera Blue Cross and Quartet Partner
Post on 10/3/16
-
Better Buy: GlaxoSmithKline plc vs. Johnson & Johnson
Post on 10/3/16
-
Celgene Is Building an Autoimmune Empire -- and No One Is Talking About It
Post on 10/3/16
-
Is Celgene the Smartest Buyer in Biotech?
Post on 10/3/16
-
Hillary Clinton vs. Donald Trump on Obamacare
Post on 10/3/16
-
Delcath Prices Stock Offering
Post on 10/2/16
-
Bristol-Myers Squibb (BMY) Presents at Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference (Transcript)
Post on 9/30/16
-
Highlighting New York City's Best Fitness Rooms
Post on 9/30/16
-
ContraVir to Receive $1.8 Million Through New Jersey Technology Business Tax Certificate Transfer Program
Post on 9/29/16
-
Actinium Prices Stock Offering
Post on 9/29/16
-
Pfizer: No Buy Signal After The Dip
Post on 9/29/16
-
Johnson & Johnson: Buying The Dips Beats The Drips - Timing Not An Issue
Post on 9/29/16
-
Better Buy: Johnson & Johnson vs. AbbVie
Post on 9/29/16
-
Tabula Rasa HealthCare Prices IPO
Post on 9/29/16
-
Foamix Pharmaceuticals Prices $57 Million Follow-on Offering of Ordinary Shares
Post on 9/28/16
-
Genoa to Open Its First Integrated Behavioral Health Pharmacy in New York
Post on 9/28/16
New York
